A Phase 3B, Open Label, Multi-Center Study to Evaluate the Safety, Tolerability and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Alone to Healthy Infants According to Different Immunization Schedules and to Healthy Children Aged 2 to 10 Years

Conditions

• Meningococcal Disease
• Meningococcal Meningitis

Interventions

• BIOLOGICAL: rMenB + OMV NZ vaccine
• BIOLOGICAL: rMenB + OMV NZ vaccine
• BIOLOGICAL: rMenB + OMV NZ vaccine
• BIOLOGICAL: rMenB + OMV NZ vaccine
• BIOLOGICAL: Meningococcal C oligosaccharide conjugated vaccine
• BIOLOGICAL: Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
• BIOLOGICAL: rMenB + OMV NZ vaccine
• BIOLOGICAL: rMenB + OMV NZ vaccine

Sponsor

Novartis Vaccines